• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Legal Officer Klinger Shannon Thyme converted options into 233 shares and covered exercise/tax liability with 113 shares, increasing direct ownership by 0.46% to 26,300 units (SEC Form 4)

    6/2/25 4:33:25 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MRNA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Klinger Shannon Thyme

    (Last) (First) (Middle)
    C/O MODERNA, INC.
    325 BINNEY STREET

    (Street)
    CAMBRIDGE MA 02142

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Moderna, Inc. [ MRNA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Legal Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/30/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/30/2025 M(1) 233 A (1) 26,413 D
    Common Stock 05/30/2025 F(2) 113 D $26.93 26,300 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 05/30/2025 M(1) 233 (3) (3) Common Stock 233 $0 698 D
    Explanation of Responses:
    1. Restricted stock units convert into common stock on a one-for-one basis.
    2. Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
    3. 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
    /s/ James Dillon, as Attorny-in-Fact 06/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRNA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Neutral
    Citigroup
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    12/18/2024Buy → Hold
    Argus
    12/10/2024$41.00Underperform
    BofA Securities
    11/19/2024$42.00Hold
    Berenberg
    11/18/2024$58.00Hold → Buy
    HSBC Securities
    11/15/2024$40.00Underperform
    Wolfe Research
    More analyst ratings

    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Moderna with a new price target

      Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

      3/13/25 8:15:14 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna downgraded by Barclays with a new price target

      Barclays downgraded Moderna from Overweight to Equal Weight and set a new price target of $45.00 from $111.00 previously

      2/18/25 7:11:52 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna downgraded by Goldman with a new price target

      Goldman downgraded Moderna from Buy to Neutral and set a new price target of $51.00 from $99.00 previously

      1/29/25 7:08:27 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare

      Etiome's Temporal Biodynamics™ AI-powered platform is the first end-to-end solution to detect disease and preempt progression before it becomes too late Company emerges following four years of platform development and an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Etiome, a company redefining how we detect and preempt disease progression. Etiome's Temporal Biodynamics™ platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcom

      4/24/25 6:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Financials

    Live finance-specific insights

    See more
    • Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

      Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I

      11/7/24 6:30:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

      CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv

      10/17/24 7:05:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

      Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billionReceived U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in JuneAnnounced positive Phase 3 data for combination vaccine against influenza and COVID-19Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our

      8/1/24 6:30:00 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      4/10/24 2:03:52 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      2/7/24 8:42:56 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      1/29/24 3:26:24 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Moderna Inc.

      SCHEDULE 13G - Moderna, Inc. (0001682852) (Subject)

      5/12/25 10:36:17 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Moderna Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Moderna, Inc. (0001682852) (Filer)

      5/5/25 4:03:04 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Moderna Inc.

      10-Q - Moderna, Inc. (0001682852) (Filer)

      5/1/25 4:02:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $MRNA
    Leadership Updates

    Live Leadership Updates

    See more

    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health

      Owen joins to lead new phase of growth for the medical device company in clinical trial, diagnostic, and reference laboratory applications CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the appointment of Paul Owen as Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering. Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most r

      2/19/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • President Hoge Stephen converted options into 652 shares and covered exercise/tax liability with 316 shares, increasing direct ownership by 0.02% to 1,452,119 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      6/2/25 4:36:37 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Klinger Shannon Thyme converted options into 233 shares and covered exercise/tax liability with 113 shares, increasing direct ownership by 0.46% to 26,300 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      6/2/25 4:33:25 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 4% to 16,191 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/29/25 5:16:01 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care